Gene landscape and correlation between B-cell infiltration and programmed death ligand 1 expression in lung adenocarcinoma patients from The Cancer Genome Atlas data set
Authors:
Open Access
- 6 December 2018
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (12) , e0208459
Abstract
Tumor-infiltrating lymphocytes are related to positive clinical prognoses in numerous cancer types. Programmed death ligand 1 (PD-L1), a mediator of the PD-1 receptor, plays an inhibitory role in cancer immune responses. PD-L1 upregulation can impede infiltrating T-cell functions in lung adenocarcinoma (LUAD), a lung cancer subtype. However, associations between the expression of PD-L1 and infiltration of B cells (a major immunoregulatory cell) remain unknown. Therefore, we investigated the role of infiltrating B cells in LUAD progression and its correlation with PD-L1 expression. The Cancer Genome Atlas (TCGA) LUAD data set was used to explore associations among B-cell infiltration, PD-L1 expression, clinical outcome, and gene landscape. Gene set enrichment analysis was used to explore putative signaling pathways and candidate genes. The drug enrichment analysis was used to identify candidate genes and the related drugs. We found that high B-cell infiltration was correlated with better prognoses; however, PD-L1 may interfere with the survival advantage in patients with high B-cell infiltration. The gene landscape was characterized comprehensively, with distinct PD-L1 levels in cell populations with high B-cell infiltration. We obtained five upregulated signaling pathways from the gene landscape: apoptosis, tumor necrosis factor (TNF)-α signaling via nuclear factor (NF)-κB, apical surface, interferon-α response, and KRAS signaling. Moreover, four candidate genes and their related target drugs were also identified, namely interleukin-2β receptor (IL2RB), IL-2γ receptor (IL2RG), Toll-like receptor 8 (TLR8), and TNF. These findings suggest that tumor-infiltrating B cells could act as a clinical factor in anti-PD-L1 immunotherapy for LUAD.Keywords
Funding Information
- Ministry of Science and Technology, Taiwan (MOST 106-2320-B-038-051-MY3)
- Taipei city government contract (105XDAA00013)
- Taipei city government contract (106XDAA00014)
- Taipei City Hospital Ren-Ai Branch (TPCH-106-020)
- Taipei City Hospital Ren-Ai Branch (TPCH-107-020)
- Cathay General Hospital (106CGH-TMU-06)
- Taipei Medical University (106-1200-008-110)
This publication has 39 references indexed in Scilit:
- The Emerging Role of B Cells in Tumor ImmunityCancer Research, 2016
- Immune Checkpoint Blockade in Cancer TherapyJournal of Clinical Oncology, 2015
- Tumor-infiltrating B cells come into vogueWorld Journal of Gastroenterology, 2013
- Tumor-infiltrating B cellsOncoImmunology, 2012
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- CD20+ B Cells: The Other Tumor-Infiltrating LymphocytesThe Journal of Immunology, 2010
- B-cell-derived lymphotoxin promotes castration-resistant prostate cancerNature, 2010
- Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical OutcomeScience, 2006
- De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependentCancer Cell, 2005
- B‐Lymphocytes Activated by CD40 Ligand Induce an Antigen‐Specific Anti‐Tumour Immune Response by Direct and Indirect Activation of CD8+ T‐cellsScandinavian Journal of Immunology, 2004